{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:18:09Z","timestamp":1792793889713,"version":"4.5.0"},"reference-count":49,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2020,10,30]],"date-time":"2020-10-30T00:00:00Z","timestamp":1604016000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,4,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The protein kinase ataxia telangiectasia mutated (ATM) mediates cellular response to DNA damage induced by radiation. ATM inhibition decreases DNA damage repair in tumor cells and affects tumor growth. AZD1390 is a novel, highly potent, selective ATM inhibitor designed to cross the blood\u2013brain barrier (BBB) and currently evaluated with radiotherapy in a phase I study in patients with brain malignancies. In the present study, PET was used to measure brain exposure of 11C-labeled AZD1390 after intravenous (i.v.) bolus administration in healthy subjects with an intact BBB.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>AZD1390 was radiolabeled with carbon-11 and a microdose (mean injected mass 1.21 \u00b5g) was injected in 8 male subjects (21\u201365 y). The radioactivity concentration of [11C]AZD1390 in brain was measured using a high-resolution PET system. Radioactivity in arterial blood was measured to obtain a metabolite corrected arterial input function for quantitative image analysis. Participants were monitored by laboratory examinations, vital signs, electrocardiogram, adverse events.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The brain radioactivity concentration of [11C]AZD1390 was 0.64 SUV (standard uptake value) and reached maximum 1.00% of injected dose at Tmax[brain] of 21 min (time of maximum brain radioactivity concentration) after i.v. injection. The whole brain total distribution volume was 5.20 mL*cm\u22123. No adverse events related to [11C]AZD1390 were reported.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>This study demonstrates that [11C]AZD1390 crosses the intact BBB and supports development of AZD1390 for the treatment of glioblastoma multiforme or other brain malignancies. Moreover, it illustrates the potential of PET microdosing in predicting and guiding dose range and schedule for subsequent clinical studies.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/neuonc\/noaa238","type":"journal-article","created":{"date-parts":[[2020,10,14]],"date-time":"2020-10-14T19:26:26Z","timestamp":1602703586000},"page":"687-696","source":"Crossref","is-referenced-by-count":65,"title":["Brain exposure of the ATM inhibitor AZD1390 in humans\u2014a positron emission tomography study"],"prefix":"10.1093","volume":"23","author":[{"given":"Aurelija","family":"Jucaite","sequence":"first","affiliation":[{"name":"PET Science Centre, Precision Medicine and Biosamples, R&D, AstraZeneca, Stockholm, Sweden"},{"name":"Department of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet and Stockholm County Council, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Stenkrona","sequence":"additional","affiliation":[{"name":"Department of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet and Stockholm County Council, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zsolt","family":"Csel\u00e9nyi","sequence":"additional","affiliation":[{"name":"PET Science Centre, Precision Medicine and Biosamples, R&D, AstraZeneca, Stockholm, Sweden"},{"name":"Department of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet and Stockholm County Council, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"De Vita","sequence":"additional","affiliation":[{"name":"Oncology R&D, AstraZeneca, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuria","family":"Buil-Bruna","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarina","family":"Varn\u00e4s","sequence":"additional","affiliation":[{"name":"Department of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet and Stockholm County Council, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Savage","sequence":"additional","affiliation":[{"name":"Oncology R&D, AstraZeneca, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Varrone","sequence":"additional","affiliation":[{"name":"Department of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet and Stockholm County Council, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Johnstr\u00f6m","sequence":"additional","affiliation":[{"name":"PET Science Centre, Precision Medicine and Biosamples, R&D, AstraZeneca, Stockholm, Sweden"},{"name":"Department of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet and Stockholm County Council, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magnus","family":"Schou","sequence":"additional","affiliation":[{"name":"PET Science Centre, Precision Medicine and Biosamples, R&D, AstraZeneca, Stockholm, Sweden"},{"name":"Department of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet and Stockholm County Council, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Davison","sequence":"additional","affiliation":[{"name":"Oncology R&D, AstraZeneca, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andy","family":"Sykes","sequence":"additional","affiliation":[{"name":"Oncology R&D, AstraZeneca, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venkatesh","family":"Pilla Reddy","sequence":"additional","affiliation":[{"name":"Oncology R&D, AstraZeneca, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Hoch","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Vazquez-Romero","sequence":"additional","affiliation":[{"name":"Department of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet and Stockholm County Council, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Mahdi","family":"Moein","sequence":"additional","affiliation":[{"name":"Department of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet and Stockholm County Council, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christer","family":"Halldin","sequence":"additional","affiliation":[{"name":"Department of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet and Stockholm County Council, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melinda S","family":"Merchant","sequence":"additional","affiliation":[{"name":"Oncology R&D, AstraZeneca, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Pass","sequence":"additional","affiliation":[{"name":"Oncology R&D, AstraZeneca, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Farde","sequence":"additional","affiliation":[{"name":"PET Science Centre, Precision Medicine and Biosamples, R&D, AstraZeneca, Stockholm, Sweden"},{"name":"Department of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet and Stockholm County Council, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,10,30]]},"reference":[{"issue":"17","key":"2021041218433033600_CIT0001","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1001\/jama.2013.280319","article-title":"Glioblastoma and other malignant gliomas: a clinical review","volume":"310","author":"Omuro","year":"2013","journal-title":"JAMA."},{"issue":"2","key":"2021041218433033600_CIT0002","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s40263-016-0405-9","article-title":"Crossing the blood-brain barrier: recent advances in drug delivery to the brain","volume":"31","author":"Patel","year":"2017","journal-title":"CNS Drugs."},{"issue":"5","key":"2021041218433033600_CIT0003","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.drudis.2019.01.015","article-title":"Building on the success of osimertinib: achieving CNS exposure in oncology drug discovery","volume":"24","author":"Colclough","year":"2019","journal-title":"Drug Discov Today."},{"issue":"5366","key":"2021041218433033600_CIT0004","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1126\/science.280.5366.1089","article-title":"Requirement for ATM in ionizing radiation-induced cell death in the developing central nervous system","volume":"280","author":"Herzog","year":"1998","journal-title":"Science."},{"issue":"6922","key":"2021041218433033600_CIT0005","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/nature01368","article-title":"DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation","volume":"421","author":"Bakkenist","year":"2003","journal-title":"Nature."},{"issue":"8","key":"2021041218433033600_CIT0006","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.1172\/JCI77195","article-title":"Radiation and ATM inhibition: the heart of the matter","volume":"124","author":"Hammond","year":"2014","journal-title":"J Clin Invest."},{"key":"2021041218433033600_CIT0007","doi-asserted-by":"crossref","first-page":"107391","DOI":"10.1016\/j.pharmthera.2019.07.002","article-title":"ATM in DNA repair in cancer","volume":"203","author":"Jin","year":"2019","journal-title":"Pharmacol Ther."},{"issue":"20","key":"2021041218433033600_CIT0008","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1158\/0008-5472.CAN-14-3790","article-title":"Selective inhibition of parallel DNA damage response pathways optimizes radiosensitization of glioblastoma stem-like cells","volume":"75","author":"Ahmed","year":"2015","journal-title":"Cancer Res."},{"issue":"6","key":"2021041218433033600_CIT0009","doi-asserted-by":"crossref","first-page":"eaat1719","DOI":"10.1126\/sciadv.aat1719","article-title":"The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizers and improves survival of preclinical brain tumour models","volume":"4","author":"Durant","year":"2018","journal-title":"Sci Adv."},{"issue":"5\u20136","key":"2021041218433033600_CIT0010","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s00228-003-0643-x","article-title":"Positron emission tomography microdosing: a new concept with application in tracer and early clinical drug development","volume":"59","author":"Bergstr\u00f6m","year":"2003","journal-title":"Eur J Clin Pharmacol."},{"issue":"12","key":"2021041218433033600_CIT0011","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1111\/j.1468-2982.2005.00966.x","article-title":"Distribution of intranasal C-zolmitriptan assessed by positron emission tomography","volume":"25","author":"Yates","year":"2005","journal-title":"Cephalalgia."},{"issue":"4","key":"2021041218433033600_CIT0012","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1177\/0271678X19843776","article-title":"A PET study in healthy subjects of brain exposure of 11C-labelled osimertinib\u2014a drug intended for treatment of brain metastases in non-small cell lung cancer","volume":"40","author":"Varrone","year":"2020","journal-title":"J Cereb Blood Flow Metab."},{"issue":"3","key":"2021041218433033600_CIT0013","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/nrd1037","article-title":"Big physics, small doses: the use of AMS and PET in human microdosing of development drugs","volume":"2","author":"Lappin","year":"2003","journal-title":"Nat Rev Drug Discov."},{"issue":"6","key":"2021041218433033600_CIT0014","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.tips.2006.04.004","article-title":"Using positron emission tomography to facilitate CNS drug development","volume":"27","author":"Lee","year":"2006","journal-title":"Trends Pharmacol Sci."},{"issue":"10","key":"2021041218433033600_CIT0015","doi-asserted-by":"crossref","first-page":"pyv036","DOI":"10.1093\/ijnp\/pyv036","article-title":"Large variation in brain exposure of reference CNS drugs: a PET study in non-human primates","volume":"18","author":"Schou","year":"2015","journal-title":"Int J Neuropsyhopharmacol."},{"issue":"5","key":"2021041218433033600_CIT0016","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/S0969-8051(99)00005-0","article-title":"Carbon-11 epidepride: a suitable radioligand for PET investigation of striatal and extrastriatal dopamine D2 receptors","volume":"26","author":"Langer","year":"1999","journal-title":"Nucl Med Biol."},{"issue":"1","key":"2021041218433033600_CIT0017","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1097\/00004728-198102000-00027","article-title":"Head fixation device for reproducible position alignment in transmission CT and positron emission tomography","volume":"5","author":"Bergstr\u00f6m","year":"1981","journal-title":"J Comput Assist Tomogr."},{"issue":"10","key":"2021041218433033600_CIT0018","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1007\/s00259-009-1156-3","article-title":"Advancement in PET quantification using 3D-OP-OSEM point spread function reconstruction with the HRRT","volume":"36","author":"Varrone","year":"2009","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"4","key":"2021041218433033600_CIT0019","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1007\/s00216-012-6541-2","article-title":"Identification of PET radiometabolites by cytochrome P450, UHPLC\/Q-ToF-MS and fast radio-LC: applied to the PET radioligands [11C]flumazenil, [18F]FE-PE2I, and [11C]PBR28","volume":"405","author":"Amini","year":"2013","journal-title":"Anal Bioanal Chem."},{"key":"2021041218433033600_CIT0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.trac.2018.10.019","article-title":"Sample preparation techniques for radiometabolite analysis of positron emission tomography radioligands; trends, progress, limitations and future prospects","volume":"110","author":"Moein","year":"2019","journal-title":"TRAC-Trends Anal Chem."},{"issue":"5","key":"2021041218433033600_CIT0021","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1038\/jcbfm.1989.98","article-title":"Kinetic analysis of central [11C]raclopride binding to D2-dopamine receptors studied by PET\u2013a comparison to the equilibrium analysis","volume":"9","author":"Farde","year":"1989","journal-title":"J Cereb Blood Flow Metab."},{"key":"2021041218433033600_CIT0022","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3402\/bindslev.2008.14","volume-title":"Drug-Acceptor Interactions.","author":"Bindslev","year":"2008"},{"issue":"9","key":"2021041218433033600_CIT0023","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1038\/jcbfm.2015.66","article-title":"Quantification of blood flow-dependent component in estimates of beta-amyloid load obtained using quasi-steady-state standardized uptake value ratio","volume":"35","author":"Csel\u00e9nyi","year":"2015","journal-title":"J Cereb Blood Flow Metab."},{"issue":"1","key":"2021041218433033600_CIT0024","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1006\/nimg.2001.0978","article-title":"Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain","volume":"15","author":"Tzourio-Mazoyer","year":"2002","journal-title":"Neuroimage."},{"issue":"3","key":"2021041218433033600_CIT0025","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/ana.410150302","article-title":"A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography","volume":"15","author":"Mintun","year":"1984","journal-title":"Ann Neurol."},{"issue":"6","key":"2021041218433033600_CIT0026","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1124\/dmd.108.026377","article-title":"Development of a high-throughput brain slice method for studying drug distribution in the central nervous system","volume":"37","author":"Frid\u00e9n","year":"2009","journal-title":"Drug Metab Dispos."},{"issue":"7","key":"2021041218433033600_CIT0027","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1124\/dmd.111.038778","article-title":"Species independence in brain tissue binding using brain homogenates","volume":"39","author":"Di","year":"2011","journal-title":"Drug Metab Dispos."},{"key":"2021041218433033600_CIT0028","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1109\/TAC.1974.1100705","article-title":"A new look at the statistical model identification","volume":"19","author":"Akaike","year":"1974","journal-title":"IEEE Trans Autom Control."},{"key":"2021041218433033600_CIT0029","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13550-015-0103-5","article-title":"Lapatinib access into normal brain and brain metastases in patients with Her-2 overexpressing breast cancer","volume":"5","author":"Saleem","year":"2015","journal-title":"EJNMMI Res."},{"issue":"20","key":"2021041218433033600_CIT0030","doi-asserted-by":"crossref","first-page":"5130","DOI":"10.1158\/1078-0432.CCR-16-0399","article-title":"Preclinical comparison of osimertinib with other EGFR-TKIs in EGFR-mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity","volume":"22","author":"Ballard","year":"2016","journal-title":"Clin Cancer Res."},{"issue":"10","key":"2021041218433033600_CIT0031","doi-asserted-by":"crossref","first-page":"S842","DOI":"10.1016\/j.jtho.2019.08.1818","article-title":"An open-label PET-MRI study to determine brain exposure of osimertinib in patients with EGFR mutant NSCLC and CNS metastases","volume":"14","author":"Ekman","year":"2019","journal-title":"J Thoracic Oncol."},{"issue":"3","key":"2021041218433033600_CIT0032","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1517\/17425250903559873","article-title":"Assessing brain free fraction in early drug discovery","volume":"6","author":"Read","year":"2010","journal-title":"Expert Opin Drug Metab Toxicol."},{"issue":"8","key":"2021041218433033600_CIT0033","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1007\/s11095-007-9502-2","article-title":"On the rate and extent of drug delivery to the brain","volume":"25","author":"Hammarlund-Udenaes","year":"2008","journal-title":"Pharm Res."},{"issue":"1","key":"2021041218433033600_CIT0034","doi-asserted-by":"crossref","first-page":"5308","DOI":"10.1038\/s41598-019-41828-4","article-title":"Heterogeneous drug tissue binding in brain regions of rats, Alzheimer\u2019s patients and controls: impact on translational drug development","volume":"9","author":"Gustafsson","year":"2019","journal-title":"Sci Rep."},{"issue":"5","key":"2021041218433033600_CIT0035","doi-asserted-by":"crossref","first-page":"807","DOI":"10.2967\/jnumed.108.058453","article-title":"Human brain imaging and radiation dosimetry of 11C-N-desmethyl-loperamide, a PET radiotracer to measure the function of P-glycoprotein","volume":"50","author":"Seneca","year":"2009","journal-title":"J Nucl Med."},{"key":"2021041218433033600_CIT0036","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.neuroimage.2013.08.035","article-title":"Characterization of [(11)C]Cimbi-36 as an agonist PET radioligand for the 5-HT(2A) and 5-HT(2C) receptors in the nonhuman primate brain","volume":"84","author":"Finnema","year":"2014","journal-title":"Neuroimage."},{"issue":"6","key":"2021041218433033600_CIT0037","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1111\/j.1471-4159.1992.tb10978.x","article-title":"Blood-cerebrospinal fluid and blood-brain barriers imaged by 18F-labeled metabolites of 18F-setoperone studied in humans using positron emission tomography","volume":"58","author":"Blin","year":"1992","journal-title":"J Neurochem."},{"issue":"19","key":"2021041218433033600_CIT0038","doi-asserted-by":"crossref","first-page":"5415","DOI":"10.1016\/j.bmcl.2013.07.045","article-title":"Investigation of an F-18 oxytocin receptor selective ligand via PET imaging","volume":"23","author":"Smith","year":"2013","journal-title":"Bioorg Med Chem Lett."},{"issue":"6","key":"2021041218433033600_CIT0039","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1017\/S1461145712001411","article-title":"AZD5213: a novel histamine H3 receptor antagonist permitting high daytime and low nocturnal H3 receptor occupancy, a PET study in human subjects","volume":"16","author":"Jucaite","year":"2013","journal-title":"Int J Neuropsychopharmacol."},{"issue":"3","key":"2021041218433033600_CIT0040","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1177\/0271678X16650697","article-title":"Determination of receptor occupancy in the presence of mass dose: [11C]GSK189254 PET imaging of histamine H3 receptor occupancy by PF-03654746","volume":"37","author":"Gallezot","year":"2017","journal-title":"J Cereb Blood Flow Metab."},{"issue":"3","key":"2021041218433033600_CIT0041","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s11060-017-2384-1","article-title":"Choroid plexus tumors in adult and pediatric populations: the Cleveland Clinic and University Hospitals experience","volume":"132","author":"Bahar","year":"2017","journal-title":"J Neurooncol."},{"key":"2021041218433033600_CIT0042","article-title":"Pharmacokinetics, safety and tolerability of olaparib and temozolomide for recurrent glioblastoma: results of the phase I OPARATIC trial [published online ahead of print April 29, 2020]","author":"Hanna","journal-title":"Neuro Oncol."},{"issue":"4","key":"2021041218433033600_CIT0043","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1093\/neuonc\/noy004","article-title":"Drug discovery in neuro-oncology: challenges in the path forward","volume":"20","author":"Levin","year":"2018","journal-title":"Neuro Oncol."},{"issue":"2","key":"2021041218433033600_CIT0044","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1093\/neuonc\/nox175","article-title":"Is the blood-brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data","volume":"20","author":"Sarkaria","year":"2018","journal-title":"Neuro Oncol."},{"issue":"10","key":"2021041218433033600_CIT0045","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1158\/1535-7163.MCT-12-0552","article-title":"Active efflux of dasatinib from the brain limits efficacy against murine glioblastoma: broad implications for the clinical use of molecularly targeted agents","volume":"11","author":"Agarwal","year":"2012","journal-title":"Mol Cancer Ther."},{"issue":"1","key":"2021041218433033600_CIT0046","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41568-019-0205-x","article-title":"The blood-brain barrier and blood-tumour barrier in brain tumours and metastases","volume":"20","author":"Arvanitis","year":"2020","journal-title":"Nat Rev Cancer."},{"issue":"2","key":"2021041218433033600_CIT0047","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1002\/cncr.24735","article-title":"Disruption of the blood brain barrier by brain metastases of triple-negative and basal-type breast cancer but not HER2\/neu-positive breast cancer","volume":"116","author":"Yonemori","year":"2010","journal-title":"Cancer."},{"issue":"2","key":"2021041218433033600_CIT0048","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2165\/11537250-000000000-00000","article-title":"A combined accelerator mass spectrometry-positron emission tomography human microdose study with 14C- and 11C-labelled verapamil","volume":"50","author":"Wagner","year":"2011","journal-title":"Clin Pharmacokinet."},{"issue":"1","key":"2021041218433033600_CIT0049","first-page":"325","article-title":"Evaluation of cerebral pharmacokinetics of the novel antidepressant drug, BMS-181101, by positron emission tomography","volume":"279","author":"Christian","year":"1996","journal-title":"J Pharmacol Exp Ther."}],"container-title":["Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/neuro-oncology\/advance-article-pdf\/doi\/10.1093\/neuonc\/noaa238\/36801681\/noaa238.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/23\/4\/687\/37036398\/noaa238.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/23\/4\/687\/37036398\/noaa238.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,12]],"date-time":"2021-04-12T20:21:52Z","timestamp":1618258912000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article\/23\/4\/687\/5943449"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,30]]},"references-count":49,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2020,10,30]]},"published-print":{"date-parts":[[2021,4,12]]}},"URL":"https:\/\/doi.org\/10.1093\/neuonc\/noaa238","relation":{},"ISSN":["1522-8517","1523-5866"],"issn-type":[{"value":"1522-8517","type":"print"},{"value":"1523-5866","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,4,1]]},"published":{"date-parts":[[2020,10,30]]}}}